LAVA Therapeutics BV (LVTX): Price and Financial Metrics
LVTX Price/Volume Stats
| Current price | $2.64 | 52-week high | $6.47 |
| Prev. close | $2.74 | 52-week low | $1.13 |
| Day low | $2.52 | Volume | 163,700 |
| Day high | $2.85 | Avg. volume | 1,447,383 |
| 50-day MA | $2.78 | Dividend yield | N/A |
| 200-day MA | $1.91 | Market Cap | 66.92M |
LVTX Stock Price Chart Interactive Chart >
LAVA Therapeutics BV (LVTX) Company Bio
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates
Latest LVTX News From Around the Web
Below are the latest news stories about LAVA THERAPEUTICS NV that investors may wish to consider to help them evaluate LVTX as an investment opportunity.
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsLAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and tolerability utilizing the Gammabody® platform as a monotherapy in advanced EGFR expressing solid tumorsSelection of undisclosed lead candidate by Janssen Biotech triggered an onboarding milestone paymentLAVA plans to submit IND for Gammabody targeting CD123 in 1H 2024 (LAVA-1266)Strong balance sheet wit |
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceUTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a virtual fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference which will be |
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsSignificant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by SeagenPortfolio reprioritization and extension of cash runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody |
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual ConferenceUTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the H.C. Wainwright Immune Cell Engager Virtual Conference. Presentation details Fo |
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway• LAVA-1207 for the treatment of prostate cancer will continue as the lead program• LAVA-051 Phase 1/2a clinical trial will be discontinued• Associated cost savings and initiatives are expected to extend the cash runway further into 2026 UTRECHT, The Netherlands, and PHILADELPHIA, June 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers, tod |
LVTX Price Returns
| 1-mo | -32.48% |
| 3-mo | 44.26% |
| 6-mo | 120.00% |
| 1-year | 70.32% |
| 3-year | -77.14% |
| 5-year | N/A |
| YTD | 67.09% |
| 2023 | -54.86% |
| 2022 | -36.36% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...